pubmed.ncbi.nlm.nih.gov

Proteome-based plasma biomarkers for Alzheimer's disease - PubMed

. 2006 Nov;129(Pt 11):3042-50.

doi: 10.1093/brain/awl279.

Affiliations

Proteome-based plasma biomarkers for Alzheimer's disease

A Hye et al. Brain. 2006 Nov.

Abstract

Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral tissue. We performed a case-control study of plasma using this proteomics approach to identify proteins that differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with Alzheimer's dementia were recruited through secondary services and 50 normal elderly controls through primary care. For validation purposes a total of 511 subjects with Alzheimer's disease and other neurodegenerative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglobulin (alpha-2M). Using semi-quantitative immunoblotting, the elevation of CFH and alpha-2M was shown to be specific for Alzheimer's disease and to correlate with disease severity although alternative assays would be necessary to improve sensitivity and specificity. These findings suggest that blood may be a rich source for biomarkers of Alzheimer's disease and that CFH, together with other proteins such as alpha-2M may be a specific markers of this illness.

PubMed Disclaimer

Similar articles

Cited by

  • Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net.

    Shen L, Kim S, Qi Y, Inlow M, Swaminathan S, Nho K, Wan J, Risacher SL, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; ADNI. Shen L, et al. Multimodal Brain Image Anal (2011). 2011 Sep;7012:27-34. doi: 10.1007/978-3-642-24446-9_4. Multimodal Brain Image Anal (2011). 2011. PMID: 27054198 Free PMC article.

  • Pharmaceutical Advances and Proteomics Researches.

    KhalKhal E, Rezaei-Tavirani M, Rostamii-Nejad M. KhalKhal E, et al. Iran J Pharm Res. 2019 Fall;18(Suppl1):51-67. doi: 10.22037/ijpr.2020.112440.13758. Iran J Pharm Res. 2019. PMID: 32802089 Free PMC article. Review.

  • Multiplex biomarkers in blood.

    Gupta VB, Sundaram R, Martins RN. Gupta VB, et al. Alzheimers Res Ther. 2013 Jun 25;5(3):31. doi: 10.1186/alzrt185. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23795953 Free PMC article. Review.

  • Plasma based markers of [11C] PiB-PET brain amyloid burden.

    Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R; Alzheimers Disease Neuroimaging Initiative. Kiddle SJ, et al. PLoS One. 2012;7(9):e44260. doi: 10.1371/journal.pone.0044260. Epub 2012 Sep 24. PLoS One. 2012. PMID: 23028511 Free PMC article.

  • Fluid biomarkers in Alzheimer disease.

    Blennow K, Zetterberg H, Fagan AM. Blennow K, et al. Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221. Cold Spring Harb Perspect Med. 2012. PMID: 22951438 Free PMC article. Review.

Publication types

MeSH terms

Substances